SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Shares Sold by LS Investment Advisors LLC

LS Investment Advisors LLC lowered its position in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) by 1.1% during the second quarter, Holdings Channel reports. The institutional investor owned 10,203 shares of the specialty pharmaceutical company’s stock after selling 117 shares during the period. LS Investment Advisors LLC’s holdings in SciClone Pharmaceuticals were worth $112,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co. NY raised its position in SciClone Pharmaceuticals by 6.4% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 39,519 shares of the specialty pharmaceutical company’s stock worth $427,000 after buying an additional 2,389 shares in the last quarter. Teachers Advisors LLC raised its position in SciClone Pharmaceuticals by 3.0% in the fourth quarter. Teachers Advisors LLC now owns 80,483 shares of the specialty pharmaceutical company’s stock worth $869,000 after buying an additional 2,370 shares in the last quarter. Louisiana State Employees Retirement System raised its position in SciClone Pharmaceuticals by 2.4% in the first quarter. Louisiana State Employees Retirement System now owns 21,000 shares of the specialty pharmaceutical company’s stock worth $206,000 after buying an additional 500 shares in the last quarter. Navellier & Associates Inc raised its position in SciClone Pharmaceuticals by 9.4% in the first quarter. Navellier & Associates Inc now owns 30,439 shares of the specialty pharmaceutical company’s stock worth $298,000 after buying an additional 2,614 shares in the last quarter. Finally, Fisher Asset Management LLC raised its position in SciClone Pharmaceuticals by 33.9% in the first quarter. Fisher Asset Management LLC now owns 155,623 shares of the specialty pharmaceutical company’s stock worth $1,525,000 after buying an additional 39,406 shares in the last quarter. 71.84% of the stock is owned by hedge funds and other institutional investors.

SciClone Pharmaceuticals, Inc. (SCLN) traded up 0.45% on Friday, reaching $11.05. 633,614 shares of the company’s stock were exchanged. The firm’s 50-day moving average is $10.97 and its 200-day moving average is $10.15. SciClone Pharmaceuticals, Inc. has a 12 month low of $8.55 and a 12 month high of $11.43. The firm has a market cap of $576.71 million, a PE ratio of 13.63 and a beta of 1.71.

SciClone Pharmaceuticals (NASDAQ:SCLN) last announced its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.02. SciClone Pharmaceuticals had a net margin of 25.18% and a return on equity of 21.10%. The company had revenue of $44.52 million during the quarter. On average, equities analysts forecast that SciClone Pharmaceuticals, Inc. will post $0.94 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://stocknewstimes.com/2017/08/12/sciclone-pharmaceuticals-inc-nasdaqscln-shares-sold-by-ls-investment-advisors-llc.html.

Separately, Maxim Group set a $14.00 target price on shares of SciClone Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, May 11th.

In other news, CEO Friedhelm Blobel sold 21,464 shares of SciClone Pharmaceuticals stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $9.32, for a total value of $200,044.48. Following the completion of the transaction, the chief executive officer now owns 107,692 shares of the company’s stock, valued at approximately $1,003,689.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Wilson Wai-Shun Cheung sold 40,500 shares of SciClone Pharmaceuticals stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $10.75, for a total transaction of $435,375.00. Following the completion of the transaction, the chief financial officer now directly owns 14,372 shares of the company’s stock, valued at approximately $154,499. The disclosure for this sale can be found here. In the last three months, insiders sold 235,500 shares of company stock valued at $2,479,764. Insiders own 5.16% of the company’s stock.

About SciClone Pharmaceuticals

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Want to see what other hedge funds are holding SCLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN).

Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply